Last reviewed · How we verify

VIMOVO 375/20

Amgen · FDA-approved active Small molecule Under review

VIMOVO 375/20 is a NSAID with proton pump inhibitor combination Small molecule drug developed by Amgen. It is currently FDA-approved for Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers. Also known as: naproxen/esomeprazole.

VIMOVO combines naproxen (an NSAID) with esomeprazole (a proton pump inhibitor) to reduce pain and inflammation while protecting the stomach from NSAID-induced ulcers.

VIMOVO 375/20 is a medication that has been studied in a safety trial for adolescents with Juvenile Idiopathic Arthritis (JIA). It is a combination of naproxen and esomeprazole in a 375 mg/20 mg dosage.

At a glance

Generic nameVIMOVO 375/20
Also known asnaproxen/esomeprazole
SponsorAmgen
Drug classNSAID with proton pump inhibitor combination
TargetCOX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole)
ModalitySmall molecule
Therapeutic areaRheumatology / Pain Management
PhaseFDA-approved

Mechanism of action

Naproxen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Esomeprazole suppresses gastric acid secretion by inhibiting the H+/K+-ATPase pump, protecting the gastric mucosa from NSAID-related damage and ulceration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about VIMOVO 375/20

What is VIMOVO 375/20?

VIMOVO 375/20 is a NSAID with proton pump inhibitor combination drug developed by Amgen, indicated for Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers.

How does VIMOVO 375/20 work?

VIMOVO combines naproxen (an NSAID) with esomeprazole (a proton pump inhibitor) to reduce pain and inflammation while protecting the stomach from NSAID-induced ulcers.

What is VIMOVO 375/20 used for?

VIMOVO 375/20 is indicated for Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers.

Who makes VIMOVO 375/20?

VIMOVO 375/20 is developed and marketed by Amgen (see full Amgen pipeline at /company/amgen).

Is VIMOVO 375/20 also known as anything else?

VIMOVO 375/20 is also known as naproxen/esomeprazole.

What drug class is VIMOVO 375/20 in?

VIMOVO 375/20 belongs to the NSAID with proton pump inhibitor combination class. See all NSAID with proton pump inhibitor combination drugs at /class/nsaid-with-proton-pump-inhibitor-combination.

What development phase is VIMOVO 375/20 in?

VIMOVO 375/20 is FDA-approved (marketed).

What are the side effects of VIMOVO 375/20?

Common side effects of VIMOVO 375/20 include Dyspepsia, Diarrhea, Abdominal pain, Nausea, Headache.

What does VIMOVO 375/20 target?

VIMOVO 375/20 targets COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole) and is a NSAID with proton pump inhibitor combination.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing